Literature DB >> 23731196

Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.

B Jonefjäll1, H Strid, L Ohman, J Svedlund, A Bergstedt, M Simren.   

Abstract

BACKGROUND: Gastrointestinal symptoms compatible with Irritable Bowel Syndrome (IBS) are common in patients with inflammatory bowel disease. It has been suggested that these symptoms are a reflection of occult inflammation rather than coexisting IBS. The aim of this study was to characterize IBS-like symptoms in patients with Ulcerative Colitis (UC) in clinical remission by assessing inflammatory markers, psychological symptoms, and quality of life.
METHODS: Ninety-four patients with new onset of UC were followed prospectively during 3 years with yearly follow-up visits. The patients completed self-administrated questionnaires. Fecal calprotectin was used as an inflammatory biomarker. Remission was defined as a total Mayo-score ≤2 and an endoscopic subscore ≤1, with no relapse during the 3-month period prior to visit. KEY
RESULTS: The prevalence of patients that fulfilled Rome II criteria for IBS among UC patients in remission was 11% at visit 1, 23% at visit 2, and 17% at visit 3. When comparing UC patients in remission with and without IBS-like symptom, patients with IBS-like symptoms had more severe gastrointestinal symptoms, tendencies toward more severe psychological symptoms and reduced levels of quality of life, but the calprotectin levels did not differ between the two groups. CONCLUSIONS & INFERENCES: IBS-like symptoms are common in patients with UC in clinical remission and these fluctuate over time. The symptoms are associated with poor psychological well-being and reduced quality of life, and do not seem to be a reflection of low-grade inflammatory activity.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Fecal Calprotectin; Functional GI symptoms; IBD; IBS; Ulcerative Colitis

Mesh:

Substances:

Year:  2013        PMID: 23731196     DOI: 10.1111/nmo.12163

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  24 in total

Review 1.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

2.  Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients.

Authors:  Arvind I Srinath; Alka Goyal; Lori A Zimmerman; Melissa C Newara; Margaret A Kirshner; Francis Nicole McCarthy; David Keljo; David Binion; Athos Bousvaros; David R DeMaso; Ada Youk; Eva M Szigethy
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

Review 3.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

Review 4.  Gastrointestinal motility disorders in inflammatory bowel diseases.

Authors:  Gabrio Bassotti; Elisabetta Antonelli; Vincenzo Villanacci; Marianna Salemme; Manuela Coppola; Vito Annese
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population.

Authors:  A D Lee; B M Spiegel; R D Hays; G Y Melmed; R Bolus; D Khanna; P P Khanna; L Chang
Journal:  Neurogastroenterol Motil       Date:  2016-12-16       Impact factor: 3.598

6.  Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Anna-Maija Puolanne; Kaija-Leena Kolho; Henrik Alfthan; Ari Ristimäki; Harri Mustonen; Martti Färkkilä
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

Review 7.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

8.  Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

Authors:  Anders Lasson; Lena Öhman; Per-Ove Stotzer; Stefan Isaksson; Otto Überbacher; Kjell-Arne Ung; Hans Strid
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

Review 9.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

10.  Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis.

Authors:  Börje Jonefjäll; Magnus Simrén; Anders Lasson; Lena Öhman; Hans Strid
Journal:  United European Gastroenterol J       Date:  2017-04-03       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.